{"id":75310,"date":"2026-08-19T12:25:08","date_gmt":"2026-08-19T04:25:08","guid":{"rendered":"https:\/\/flcube.com\/?p=75310"},"modified":"2026-08-19T12:25:09","modified_gmt":"2026-08-19T04:25:09","slug":"cspc-pharmaceuticals-anbenitamab-kn026-plus-hb1801-nda-accepted-by-nmpa-for-first-line-advanced-breast-cancer-her2-bispecific-combo-advances-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75310","title":{"rendered":"CSPC Pharmaceutical&#8217;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that the <strong>New Drug Application (NDA)<\/strong> for its <strong>bispecific antibody anbenitamab (KN026)<\/strong> in combination with its independently developed <strong>docetaxel for injection (albumin\u2011bound) (HB1801)<\/strong> has been <strong>accepted by China&#8217;s National Medical Products Administration (NMPA)<\/strong> for the <strong>first\u2011line treatment of advanced breast cancer<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anbenitamab is <strong>co\u2011developed by CSPC&#8217;s subsidiary JMT\u2011Bio and Alphamab Oncology<\/strong> (9966.HK), underscoring a multi\u2011party oncology pipeline alliance.<\/p>\n\n\n\n<h2 id=\"h-nda-summary\" class=\"wp-block-heading\">NDA Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>NDA <strong>accepted<\/strong><\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Anbenitamab (KN026) + HB1801 (albumin\u2011bound docetaxel)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line treatment of <strong>advanced breast cancer<\/strong><\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>CSPC Pharmaceutical Group (HKG: 1093)<\/td><\/tr><tr><td><strong>Co\u2011Development<\/strong><\/td><td>JMT\u2011Bio (CSPC subsidiary) \u00d7 Alphamab Oncology (9966.HK)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-anbenitamab-kn026\" class=\"wp-block-heading\">Drug Profile \u2013 Anbenitamab (KN026)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> <strong>HER2\u2011targeted bispecific antibody<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Simultaneously binds <strong>two non\u2011overlapping epitopes of HER2<\/strong>, blocking HER2 signaling, enhancing HER2 internalization, and downregulating HER2 expression<\/li>\n\n\n\n<li><strong>Effector Function:<\/strong> Retains <strong>antibody\u2011dependent cellular cytotoxicity (ADCC)<\/strong> effects<\/li>\n\n\n\n<li><strong>Prior Approval:<\/strong> In <strong>May 2026<\/strong>, anbenitamab was approved for marketing in combination with chemotherapy for adult patients with <strong>locally advanced or metastatic HER2\u2011positive gastric or gastroesophageal junction (GEJ) adenocarcinoma<\/strong> who had received at least one prior trastuzumab\u2011containing regimen<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-hb1801\" class=\"wp-block-heading\">Drug Profile \u2013 HB1801<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Novel <strong>albumin\u2011bound docetaxel formulation<\/strong><\/li>\n\n\n\n<li><strong>Design:<\/strong> Encapsulates docetaxel in <strong>human serum albumin<\/strong><\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Offers significant advantages over conventional docetaxel injections, including improved formulation characteristics typically associated with albumin\u2011bound delivery<\/li>\n\n\n\n<li><strong>Ownership:<\/strong> Independently developed by <strong>CSPC Pharmaceutical Group<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-momentum-dual-nda-acceptances\" class=\"wp-block-heading\">Regulatory Momentum \u2013 Dual NDA Acceptances<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Filing<\/th><th>Combination<\/th><th>Setting<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Prior Filing<\/strong><\/td><td>Anbenitamab + HB1801<\/td><td>Neoadjuvant therapy for <strong>HER2\u2011positive early or locally advanced breast cancer<\/strong><\/td><td>NDA accepted by NMPA<\/td><\/tr><tr><td><strong>New Filing<\/strong><\/td><td>Anbenitamab + HB1801<\/td><td><strong>First\u2011line advanced breast cancer<\/strong><\/td><td>NDA accepted by NMPA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The back\u2011to\u2011back NDA acceptances position the anbenitamab + HB1801 regimen across <strong>both early\u2011line neoadjuvant and first\u2011line advanced settings<\/strong> in HER2\u2011positive breast cancer.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanding HER2 Franchise:<\/strong> Anbenitamab&#8217;s May 2026 gastric\/GEJ approval plus two breast cancer NDAs give CSPC a fast\u2011growing, multi\u2011indication HER2 asset competing in one of oncology&#8217;s most contested targets.<\/li>\n\n\n\n<li><strong>Differentiated Backbone:<\/strong> Pairing a bispecific antibody with an <strong>albumin\u2011bound docetaxel (HB1801)<\/strong> offers a proprietary combination that rivals cannot easily replicate, strengthening CSPC&#8217;s negotiating and pricing position in China.<\/li>\n\n\n\n<li><strong>Partnership Leverage:<\/strong> The JMT\u2011Bio \u00d7 Alphamab Oncology co\u2011development model distributes R&amp;D risk while consolidating commercial upside within CSPC&#8217;s established oncology salesforce.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> NMPA review timeline for the first\u2011line breast cancer indication, potential additional combination filings, and competitive pressure from other HER2\u2011targeted agents entering the Chinese market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, clinical outcomes, and commercial expectations for anbenitamab (KN026) and HB1801. Actual results may differ due to risks including NMPA review decisions, competitive dynamics, and market adoption in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/H2_AN202608181828112922_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202608181828112922_1.\"><\/object><a id=\"wp-block-file--media-b234658f-471f-4a0f-8c09-92615e3caa28\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/H2_AN202608181828112922_1.pdf\">H2_AN202608181828112922_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/H2_AN202608181828112922_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b234658f-471f-4a0f-8c09-92615e3caa28\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,171,83,855,38],"class_list":["post-75310","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-cspc-pharmaceutical","tag-her2","tag-hkg-1093","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical&#039;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China&#039;s National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75310\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical&#039;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China&#039;s National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75310\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:25:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:25:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical&#8217;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China\",\"datePublished\":\"2026-08-19T04:25:08+00:00\",\"dateModified\":\"2026-08-19T04:25:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310\"},\"wordCount\":486,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CSPC Pharmaceutical\",\"HER2\",\"HKG: 1093\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75310#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75310\",\"name\":\"CSPC Pharmaceutical's Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:25:08+00:00\",\"dateModified\":\"2026-08-19T04:25:09+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China's National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75310\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75310#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical&#8217;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical's Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China's National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75310","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical's Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China's National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.","og_url":"https:\/\/flcube.com\/?p=75310","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:25:08+00:00","article_modified_time":"2026-08-19T04:25:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75310#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75310"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical&#8217;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China","datePublished":"2026-08-19T04:25:08+00:00","dateModified":"2026-08-19T04:25:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75310"},"wordCount":486,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CSPC Pharmaceutical","HER2","HKG: 1093","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75310#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75310","url":"https:\/\/flcube.com\/?p=75310","name":"CSPC Pharmaceutical's Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:25:08+00:00","dateModified":"2026-08-19T04:25:09+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin\u2011bound) (HB1801) has been accepted by China's National Medical Products Administration (NMPA) for the first\u2011line treatment of advanced breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75310#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75310"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75310#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical&#8217;s Anbenitamab (KN026) Plus HB1801 NDA Accepted by NMPA for First\u2011Line Advanced Breast Cancer \u2013 HER2 Bispecific Combo Advances in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75310"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75310\/revisions"}],"predecessor-version":[{"id":75312,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75310\/revisions\/75312"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}